Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 2/2008

01-06-2008 | IM - Review

Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors: Amedeo Lonardo, Paola Loria, Nicola Carulli

Published in: Internal and Emergency Medicine | Issue 2/2008

Login to get access

Abstract

Although not associated with the metabolic syndrome, HCV is linked with impaired insulin signalling, insulin resistance, hypocholesterolemia and steatosis which represent a distinct HCV-associated dysmetabolic syndrome. Insulin resistance affects the development of diabetes, fibrosis, impaired response to antivirals and perhaps hepatocellular carcinoma risk. HCV infection is associated with hypocholesterolemia and steatosis reversible after sustained virologic response. A “viral”, and a “metabolic” steatosis exist as function of viral genotypes. Little is known about the possible role of HCV in further components of the metabolic syndrome such as atherosclerosis, obesity, arterial hypertension, hyperuricemia and thrombotic risk factors.
Literature
1.
Wong T, Lee SS (2006) Hepatitis C: a review for primary care physicians. CMAJ 174:649–659PubMed
2.
Anonimymous (1999) EASL International Consensus Conference on Hepatitis C Paris, 26–27 February 1999 Consensus Statement Conference. J Hepatol 31:3–8
3.
Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis20:1–16
4.
Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G (2005) Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 76:327–332PubMed
5.
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296–305PubMed
6.
Sene D, Limal N, Cacoub P (2004) Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19:357–381PubMed
7.
Koike K, Moriya K (2005) Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 40:329–336PubMed
8.
Bach N, Thung SN, Schaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572–577PubMed
9.
Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N (2005) Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 22(Suppl 2):31–36PubMed
10.
Reisin E, Alpert MA (2005) Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 330:269–272PubMed
11.
Zambon A, Pauletto P, Crepaldi G (2005) Review article: the metabolic syndrome—a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 22(Suppl 2):20–23PubMed
12.
Ahmed I, Goldstein BJ (2006) Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med 73:759–768PubMed
13.
Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522PubMed
14.
Choi J, Ou JH (2006) Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 290:G847–G851PubMed
15.
Diaz JM, Sainz Z, Guirado LL, Ortiz-Herbener F, Picazo M, Garcia-Camin R, Palou J, Alcaraz A, Sola R (2003) Risk factors for cardiovascular disease after renal transplantation. Transplant Proc 35:1722–1724PubMed
16.
Seeff LB (1997) The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1:587–602PubMed
17.
Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T (2003) LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39:1049–1055PubMed
18.
Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G (2006) Hepatitis C and steatosis: a reappraisal. J Viral Hepat 13:73–80PubMed
19.
Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358–1364PubMed
20.
Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75–85PubMed
21.
Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P (2006) Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 44:190–196PubMed
22.
Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ (2007) Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 75:320–326PubMed
23.
Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA (2006) Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol 12:4897–4901PubMed
24.
Loria P, Lonardo A, Carulli N (2005) Should nonalcoholic fatty liver disease be renamed? Dig Dis 23:72–82PubMed
25.
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R (2007) NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 46:700–707PubMed
26.
Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840–848PubMed
27.
Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT (2004) Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77:703–710PubMed
28.
Romero-Gomez M (2006) Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Rev Esp Enferm Dig 98:605–615PubMedCrossRef
29.
Negro F (2006) Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 12:6756–6765PubMed
30.
Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H,Yoshimura A, Sata M (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499–1508PubMed
31.
Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE (2006) Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 24:1349–1357PubMed
32.
Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N (2003) Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38:1384–1392PubMed
33.
de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F (2006) Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 23:107–114PubMed
34.
35.
Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE (2006) Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55:529–535. Epub 18 Nov 2005PubMed
36.
Naunyn B (1898) Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In: Nothnagel E (ed) Der Diabetes mellitus in Handbuch. Spez Path Ther Bd 7. Holder A, Wien, pp 38–49
37.
Allison ME, Wreghitt T, Palmer CR, Alexander GJ (1994) Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135–1139PubMed
38.
Ozyilkan E, Arslan M (1996) Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 91:1480–1481PubMed
39.
Del Olmo JA, Serra MA, Rodrigo JM (1996) Liver cirrhosis and diabetes mellitus. J Hepatol 24:645PubMed
40.
Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C, Trinchet JC, Beaugrand M (1996) High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 20:544–548PubMed
41.
Fraser GM, Harman I, Meller N, Niv Y, Porath A (1996) Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 32:526–530PubMed
42.
Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, Cascavilla I, Fantasia L, Andriulli A (1998) HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol 93:2363–2367PubMed
43.
Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333PubMed
44.
Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O’Rahilly S, Shore S, Tom BD, Alexander GJ (1999) Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059–1063PubMed
45.
Macedo G, Ribeiro T (1999) Cirrhosis and diabetes: C, the difference. Am J Gastroenterol 94:3088–3089PubMed
46.
Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T (1999) High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 11:1033–1036PubMed
47.
Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A (2000) Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75:355–359PubMedCrossRef
48.
Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH (2000) Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 32:209–217PubMed
49.
Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, Kakumu S (2003) Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 38:355–360PubMed
50.
Wang CS, Wang ST, Yao WJ, Chang TT, Chou P (2003) Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol 158:1154–1160PubMed
51.
Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R (2004) High prevalence of glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care 27:1171–1175PubMed
52.
Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, Kim YS, Koo YS, Kim YK, Choi DJ, Kim JH (2005) Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 22:1530–1535PubMed
53.
Wilson C (2004) Hepatitis C infection and type 2 diabetes in American-Indian women. Diabetes Care 27:2116–2119PubMed
54.
Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B (2004) Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocr Disord 4:4PubMed
55.
Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E (2004) Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 43:238–240
56.
Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, Manesis EK (2006) Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 13:303–310PubMed
57.
Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini (2005) Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28:2548–2550PubMed
58.
Zein CO, Levy C, Basu A, Zein NN (2005) Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 100:48–55PubMed
59.
Zhao P, Wang JB, Jiao J (2006) Investigation on the incidence of diabetes in chronic hepatitis C patients and their HCV genotypes. Zhonghua Gan Zang Bing Za Zhi 14:86–88PubMed
60.
Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599PubMed
61.
Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL (2003) Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50–56PubMed
62.
El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002) Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36:1439–1445PubMed
63.
Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O’Rahilly S (1995) High Prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 12:244–249PubMedCrossRef
64.
Simo R, Hernandez C, Genesca J, Jardi R, Mesa J (1996) High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998–1000PubMed
65.
Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K et al (2000) High Prevalence and adverse effects of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 11:690–699PubMed
66.
Sotiropoulos A, Peppas TA, Skliros E, Apostolou O, Kotsini V, Pappas SI (1999) Low prevalence of hepatitis C virus infection in Greek diabetic patients. Diab Med 16:250–252
67.
Balogun WO, Adeleyde JO, Akinklade KS, Kuti M, Otegbayoe JA (2006) Low prevalence of hepatitis-C viral seropositivity among patients with type-2 diabetes mellitus in a tertiary hospital. J Natl Med Assoc 98:1805–1808PubMed
68.
Behrendt CE, Ruiz RB (2006) Hyperglycemia among persons with hepatitis C: not the classical diabetic phenotype. Diabetes Res Clin Pract 71:68–74PubMed
69.
Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L (2005) Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54:1003–1008PubMed
70.
Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J (2006) Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 44:1648–1655PubMed
71.
Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636–641PubMed
72.
D’Souza R, Sabin CA, Foster GR (2005) Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100:1509–1515PubMed
73.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539PubMed
74.
Trombetta M, Spiazzi G, Zoppini G, Muggeo M (2005) Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 22(Suppl 2):24–27PubMed
75.
Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834–3847PubMed
76.
Vollenweider P (2003) Insulin resistant states and insulin signaling. Clin Chem Lab Med 41:1107–1119PubMed
77.
Chang CK, Ulrich CM (2003) Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46:595–607PubMed
78.
Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 181:293–300
79.
Schettler V, Monazahian M, Wieland E, Ramadori G, Grunewald RW, Thomssen R, Muller GA (2001) Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Invest 31:154–155PubMed
80.
Diedrich G (2006) How does hepatitis C virus enter cells? FEBS J 273:3871–3885PubMed
81.
Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96:12766–12771PubMed
82.
Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC Jr, Min AD (2006) Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:335–340PubMed
83.
Carre D, Boucher E, Turlin B, Guyader D, Brissot P, Deugnier Y (1994) [Decrease of cholesterolemia and apolipoprotein B in chronic viral hepatitis C with massive steatosis]. Gastroenterol Clin Biol 18:899–900PubMed
84.
Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, Ideo G (1996) Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 28:436–440PubMed
85.
Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R (2001) Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428–434PubMed
86.
Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P (2002) Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 97:2880–2885PubMed
87.
Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S, Gutierrez ML, Lledo JL, Perez-Calle JL, Temino R, Cacho G, Nevado M, Casas ML, Gasalla JM, Bonet B (2006) Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 24:507–512PubMed
88.
Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J (2002) Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17:873–881PubMed
89.
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403–410PubMed
90.
Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A (2006) Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130:1661–1669PubMed
91.
Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117–125PubMed
92.
Brown MS, Goldstein JL (1981) Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 305:515–517PubMedCrossRef
93.
Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R (1999) Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57:223–229PubMed
94.
Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:586–597PubMed
95.
Lonardo A, Loria P, Bertolotti M., Carulli N (2007) Statins and HCV: a complex issue. Hepatology 45:257PubMed
96.
Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J (2001) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103:1064–1070PubMed
97.
Bilora F, Rinaldi R, Boccioletti V, Petrobelli F, Girolami A (2002) Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. Gastroenterol Clin Biol 26:1001–1004PubMed
98.
Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M (2002) Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359:133–135PubMed
99.
Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, Nagai R, Yamakado M (2003) Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67:26–30PubMed
100.
Vassalle C, Masini S, Bianchi F, Zucchelli GC (2004) Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90:565–566PubMed
101.
Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, Cook DJ, Ratliff NB, McCarthy PM, Young JB, Yamani MH (2004) Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 23:277–283PubMed
102.
Volzke H, Schwahn C, Wolff B, Mentel R, Robinson DM, Kleine V, Felix SB, John U (2004) Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 174:99–103PubMed
103.
Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA (2006) No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 43:e53–e56PubMed
104.
Sawayama Y, Okada K, Maeda S, Ohnishi H, Furusyo N, Hayashi J (2006) Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy. Fukuoka Igaku Zasshi 97:245–255PubMed
105.
Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C (2007) Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46:1126–1132PubMed
106.
Liao KF, Peng CY, Lai SW, Chang WL, Hsu NY (2006) Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan. South Med J 99:348–351PubMed
107.
Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, Melchionda N (1999) Cardiovascular disease in cirrhosis—a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 94:655–662PubMed
108.
Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM (2006) Hemostasis alterations in metabolic syndrome. Int J Mol Med 18:969–974PubMed
109.
Mato JM, Lu SC (2005) Homocysteine, the bad thiol. Hepatology 41:976–979PubMed
110.
Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D’Anto M, Capasso R, Zappia V, Ruggiero G (2005) Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41:995–1003PubMed
111.
Ratziu V, Trabut JB, Poynard T (2004) Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 6:22–29PubMed
112.
Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, Sulat-Syncerek D (2006) Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology 53:887–891PubMed
113.
Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA (2004) Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 40:147–154PubMed
114.
Solis-Herruzo JA, Perez-Carreras M, Rivas E, Fernandez-Vazquez I, Garfia C, Bernardos E, Castellano G, Colina F (2005) Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 100:1091–1098PubMed
115.
Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcon JC, Robles A (2003) Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 98:1135–1141PubMed
116.
McCullough AJ (2003) Obesity and its nurturing effect on hepatitis C. Hepatology 38:557–559PubMed
117.
Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P (1999) Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42:2204–2212PubMed
118.
Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J (2002) Multivirc group. Fatigue in patients with chronic hepatitis C. J Viral Hepat 9:295–303PubMed
119.
Tarantino G, Conca P, Sorrentino P, Ariello M (2006) Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 21:1266–1268PubMed
120.
Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55:1293–1301PubMed
121.
Grassi A, Ballardini G, Susca M, Bianchini F, Bonoli S, Bianchi FB, Lenzi M (2005) HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? Aliment Pharmacol Ther 22(Suppl 2):79–82PubMed
122.
Stanzial AM, Benoni G, Cuzzolin L, Gabrielli GB, Pasino M, Perfetti P, Corrocher R (2003) Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin. J Chemother 15:584–590PubMed
123.
Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413–419PubMed
Metadata
Title
Dysmetabolic changes associated with HCV: a distinct syndrome?
Authors
Amedeo Lonardo
Paola Loria
Nicola Carulli
Publication date
01-06-2008
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 2/2008
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-008-0127-1

Other articles of this Issue 2/2008

Internal and Emergency Medicine 2/2008 Go to the issue

CE - Letter to the Editor

Platelet dysfunction and other hemostatic disorders in women with menorrhagia: the utility of whole blood lumi-aggregometer

IM - Commentary

Should cancer patients receive thromboprophylaxis to prevent catheter-related upper limb deep vein thrombosis?

IM - Review

Optimizing management of metabolic syndrome to reduce risk: focus on life-style

EM - Original

Optical and video laryngoscopes for emergency airway management

CE - Letter to the Editor

Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma

IM - Original

Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits